ASX Research
[BUY] Amcor (ASX: AMC) – A 5.6% Yield as Volumes Turn
Amcor is a Buy with a A$81.40 target, 24.4% upside from A$65.44. June quarter volumes turned positive, EBIT rose 22%, and the unfranked yield is about 5.6%.
[BUY] Life360 (ASX: 360) – The Market Sold a 38% Revenue Quarter
Life360 grew revenue 38% and adjusted EBITDA 53% in the June quarter, yet the CDIs fell 19% on the day. We rate it a Buy with a A$30.95 target.
[BUY] Breville Group (ASX: BRG) – The Coffee Fear Is Priced In, The Margin Recovery Is Not
Breville Group (ASX: BRG) at A$31.05, on about 29x FY27 earnings and near its own ten-year average while peers re-rate. Buy, about 22% upside.
[BUY] BlueScope Steel (ASX: BSL) – Capex Peaks and Cash Flow Inflects
BlueScope Steel (ASX: BSL) at A$32.00, on 6x forward EBITDA against steel peers near 7x. Capex has peaked and free cash flow inflects. Buy, about 18% upside.
[BUY] Aristocrat Leisure (ASX: ALL) – A Billion-Dollar Interactive Path
Aristocrat Leisure (ASX: ALL) at A$61.40, charting a path to US$1bn in Interactive revenue by FY29 as iGaming and iLotteries scale. Buy, around 14% upside.
[BUY] Worley (ASX: WOR) – Selloff Overshoots the Earnings Trim
Worley (ASX: WOR) at A$10.94, around 10x forward EV/EBIT after an overdone selloff. The earnings trim is modest, the growth case intact. Buy, about 35% upside.
[BUY] ResMed (ASX: RMD) – Growth Levers in Place for a Re-Rate
Buy ResMed at A$26.68 with a A$46.70 target and 75% upside. The GLP-1 fear is fading, new growth levers are scaling, and it trades below medtech peers.
[BUY] Collins Foods (ASX: CKF) – Qld and WA Exposure Outweighs the Wage Cost Squeeze
Collins Foods (ASX: CKF) at A$8.27 trades ~20% below its historical PE. Qld/WA exposure plus a kiosk rollout offset wage pressure. 29% upside, Buy.
[BUY] WEB Travel Group (ASX: WEB): Near-Term Headwinds Create a Value Entry Point
Institutional sell-side rates WEB Travel Group a Buy with a 12-month price target of A$4.70. The stock closed at A$2.23 on 20 May 2026, implying...
[BUY] Nick Scali (ASX: NCK): Margins, Growth and a Franked Yield
Institutional sell-side rates Nick Scali a Buy with a 12-month price target of around A$20. The stock closed at approximately A$14.47 on 9 May 2026,...